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Abstract
Background: This study investigated the possible roles of arginine (Arg) in ameliorating oxidative damage of
intralipid (IL)-induced steatohepatitis (NASH).
Methods: NASH was induced in Sprague-Dawley rats by intravenous administration of 20 % IL for three weeks
and then rats were pre- and post-treated with intraperitoneal injection of Arg for two weeks. Several biochemical
parameters (blood and hepatic lipid peroxidation, glutathione, glutathione peroxidase and superoxide dismutase,
hepatic cytochrome P450 2El monooxygenase (CYP2E1), nitric oxide (NO), endothelial nitric oxide synthase (eNOS)
and tumor necrosis factor-α “TNF-α”) and liver histopathology were detected for rat groups.
Results: The administration of Arg either before or after IL significantly ameliorated uncontrolled elevation of
TBARS content, CYP2E1 activity (0.32 ± 0.01 or 0.3 ± 0.02 IU/mg) and TNF-α level. These effects were associated
with a significant increase in the levels of glutathione, activities of antioxidant enzymes, NO level (1.649 ± 0.047 or
1.957 ± 0.073 μmol/g) and activity of hepatic eNOS (0.05 ± 0.002 or 0.056 ± 0.002 IU/mg) compared to the IL-treated
rats. Moreover, the injection of Arg in NASH-induced rats showed normal hepatocytes, no steatosis and no bile
duct proliferation but mild inflammation in the group which received IL after Arg.
Conclusions: These results proved that pre- and post-treatment with Arg blocked oxidative stress-induced NASH
by inhibiting CYP2E1 activity, decreasing TNF- α level and restoration activities of eNOS and antioxidant enzymes as
well as glutathione level. This antioxidant effect of Arg leads to reverse signs of liver pathology of NASH with
amelioration of liver and kidney functions.
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Introduction
Arginine (Arg) is one of the most metabolically versatile
amino acids, serves as a precursor for synthesis of nitric
oxide (NO) and other biologically important compounds
involved in cellular homoeostasis [1]. There has been
considerable interest in the metabolism of Arg, primarily
because it is the source of NO in biological tissues from
its terminal guanidinium group by nitric oxide synthase
(NOS). Some NOS isoforms (endothelial NOS (eNOS)
and neuronal) are Ca dependent-constitutively expressed
and Ca-independent inducible NOS (iNOS) isoform [2, 3].
Arg and its product NO possess potent antistress activity
[4] thus Arg regulates cellular redox status and plays an
effective role against oxidative stress [5, 6]. Oxidative
stress plays a major role in the pathogenesis of several
liver disorders, including non-alcoholic steatohepatitis
(NASH) [7]. NASH is a severe phenotype of fatty liver
(steatosis) with the development of necroinflammatory
changes (hepatitis) that can progress to cirrhosis, with
subsequent liver failure and an increased risk of hepato-
cellular carcinoma [8].
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Free radicals accelerate the onset and progression of
NASH [9]. An overload of free radicals cannot gradually
be destroyed leads to generate deleterious processes that
can seriously alter structure and functions of the cell
membranes and macromolecules. Free radicals also en-
hance abnormal synthesis of several cytokines leading to
hepatic necroinflammatory changes [10, 11] which medi-
ated mainly through tumor necrosis factor-α (TNF-α).
TNF-α has been incriminated to play an important
pathogenic role in NASH, possibly partly related to its
ability to induce oxidative stress [12, 13]. The body has
several mechanisms to counteract oxidative stress by
producing antioxidants, which are either naturally pro-
duced in situ, or externally supplied through foods. The
endogenous cellular defense system consists of enzym-
atic scavengers (superoxide dismutase (SOD), glutathi-
one peroxidase (GPx) and others) and non-enzymatic
scavenger components such as reduced form of glutathi-
one (GSH) [14]. Several previous studies have demon-
strated the importance of GSH, SOD, and GPx in
protecting liver against oxidative damage [15, 16] which
may be mediated by hepatic microsomal cytochrome
P450 2El monooxygenase (CYP2El). CYP2El induces
fatty acid oxidation in NADPH-dependent manner pro-
ducing prooxidant species, which if not encountered by
antioxidants, may induce steatohepatitis [17].
Animal models of NASH may be divided into two
broad categories: those caused by genetic mutation and
those with an acquired phenotype produced by dietary
or pharmacological manipulation [18]. Natural nutri-
tional models have been described, including the use of
fat-rich diet that aggravates oxidative stress, leading to
steatohepatitis and provides a system for screening
therapeutic targets to treat NASH [19]. In our previous
study, El-Gamal et al (2006) [20], we reported that intra-
lipid (IL) induced hyperglycemia and dyslipidemia and
increased significantly body weight of rats which become
normalized by the injection of Arg (500 mg/Kg) for
14 days either before or after the IL administration. In
the present study, we investigated further possible roles




Fifty male Sprague-Dawely rats weighing from 110-134
were obtained from MISR University for Science and
Technology (animal welfare assurance no. A5865-01).
The animals were housed in cages with free access to
standard chow (14 % protein, 4.5 % fat, 52.9 % carbohy-
drate, 9 % fiber) and water and kept under conventional
conditions of temperature and humidity with 12 h light-
12 h dark cycle. Rats were divided randomly into five
groups; control group (the untreated normal rats), IL-
treated group (rats received a daily dose of intravenous
(i.v.) injection of 8 mL of 20 % IL/kg for three weeks),
Arg-treated group (rats received a daily dose of intraper-
itoneal (i.p.) injection of 500 mg Arg/kg for two weeks),
IL + Arg-treated group (rats i.v. injected with 20 % IL for
three weeks then treated with 500 mg Arg/kg, i.p. daily
for two weeks) and Arg + IL-treated group (rats received
500 mg Arg/kg daily for two weeks and injected with
8 mL of 20 % IL for three weeks).
At the end of the experimental period, all rats were
sacrificed by decapitation under diethyl-ether anesthesia
after an overnight fasting. Blood samples and liver tis-
sues were collected.
Determination of blood and hepatic lipid peroxidation
product levels
Lipid peroxidation was determined by measuring thio-
barbituric acid reactive substances (TBARS) in the
plasma and liver tissues as described by Ohkawa et al.
(1979) [21]. Briefly, 50 μL of plasma or liver homoge-
nates were mixed with 8.1 % SDS, 20 % acetic acid con-
taining 0.27 M HCl, pH 3.5 and 0.8 % thiobarbituric acid
(Sigma-Aldrich, USA) and heated at 95 °C for 60 min.
After cooling, 2.5 mL of n-butanol: pyridine mixture
(15:1 V/V) was added, centrifuged and the absorbances
of this organic layer were measured at 532 nm.
Determination of hepatic CYP2E1 activity
Activity of CYP2El in liver homogenate was measured
according to the method of Waxman, et al. (1989) [22].
Briefly, liver samples were mixed with 0.1 M potassium
phosphate buffer, pH 7.4 containing 8 mM aniline and
1 mM NADPH (Sigma-Aldrich, USA) and incubated for
60 min at 37 °C. The reaction was terminated with 40 %
TCA, centrifuged, 400 μL of supernatants were incu-
bated with 10 % sodium carbonate and 2 % phenol for
60 min. The absorbances of samples were read at
630 nm. Protein contents (mg) of liver samples were de-
termined using a kit obtained from Biodiagnostics,
Egypt.
Determination of hepatic NO level and eNOS activity
Nitrate plus nitrite measurement represents NO produc-
tion as described by the method of Garner et al. (1956)
[23] and its concentration was used to assess eNOS ac-
tivity as described by Giordano et al. (2002) [24] and
Chang et al. (1998) [25]. Briefly, 500 μL of liver samples
were added to the reaction mixture containing 0.1 M
Arg, 1.25 mM NADPH, 0.5 μM FAD, 0.5 μM FMN,
1 μM BH4 (Sigma-Aldrich, USA) and 10 μM CaCl2. The
mixture was incubated at 37 °C for 60 min. Five hundred
microliters of the mixture were collected for NO meas-
urement after heat inactivation, incubated with 0.96 μM
NADPH, 5 U/mL nitrate reductase and 0.1 M sodium
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phosphate buffer saline (pH 7.4) for 3 h. Finally, Griess
reagent was added to the previous mixture and absor-
bances of sample were measured at 540 nm. The total
protein contents (mg) of samples were determined as
described above.
Determination of blood and hepatic GSH levels
Content of GSH was determined in plasma and super-
natant of liver homogenates by the method of Ellman
(1959) [26]. The proteins in liver samples or plasma
were precipitated using 5 % TCA. Supernatants were in-
cubated with Ellman’s reagent and 0.2 M potassium
phosphate buffer, pH 8 for 10 min. The absorbances of
the developed yellow color of samples were measured
against blank at 412 nm.
Determination of blood and hepatic GPx activity
Total GPx activity was measured in plasma and superna-
tants of liver homogenates using the method described
by Rotruck et al. (1973) [27]. Briefly, 50 μL of plasma or
liver samples and 50 mM Tris-HCl buffer, pH 7.6
containing 0.127 mM EDTA and 1.63 mM GSH (Sigma-
Aldrich, USA) were added to 0.026 M cumene hydroper-
oxide and incubated at 37 °C for 5 min (samples). For
control, 50 μL plasma or liver samples and the previous
buffer were added to 1.63 mM GSH and incubated at
37 °C for 5 min. One milliliter of 15 % TCA was added
to control and sample and supernatants were incubated
with 19.8 mg % DTNB for 5 min. The absorbances of
samples and control were read at 412 nm.
Determination of blood and hepatic SOD activity
A simple and rapid method for the SOD activity in
plasma and liver homogenate supernatant was described
by Marklund (1974) [28]. In quartz cuvette, 1 mL of
20 mM Tris-HCl buffer, pH 8.2 containing diethylene
triaminopentaacetic acid and 20 mM pyrogallol (Sigma-
Aldrich, USA) were mixed with 20 μL of plasma, liver
samples or serial concentrations of SOD (20-200 ng/mL).
The change in the absorbance of sample and standard was
measured at 420 nm after 60 s and 120 s.
Determination of blood and hepatic TNF-α level
Livers were homogenized in phosphate buffer saline
containing 0.05 % sodium azide, 0.5 % Triton X-100 and
protease inhibitor cocktail, pH 7.2 and centrifuged at
12,000 xg for 10 min. TNF-α concentrations in plasma
and liver homogenate supernatant were measured using
a commercial rat TNF-α ELIZA kit (RayBio, USA).
Assessment of liver and kidney functions
Activities of blood alanine aminotransferase (ALT) and
aspartate aminotransferase (AST) and albumin, urea and
creatinine levels were determined in plasma samples
using kits purchased from Biodiagnostics, Egypt.
Histopathological study of liver samples
The formalin-fixed liver specimens were dehydrated in
ascending grades of alcohol then cleaned by immersion
in xylene followed by impregnation in melted paraffin
and embedding to form solid paraffin blocks. Then,
blocks were cut into 5 μm thick sections which stained
Fig. 1 Levels of blood TBARS (nmol/L) and hepatic TBARS (nmol/g) in
various animal groups. All values are expressed as the mean ± SEM
and compared with: † control group; ‡ IL-treated group; § Arg-treated
group; ¶ IL + Arg-treated group; II Arg + IL-treated group. Significance
(p < 0.05)
Fig. 2 Hepatic activity of CYP2E1 (U/mg) in various animal groups. All
values are expressed as the mean ± SEM and compared with: † control
group; ‡ IL-treated group; § Arg-treated group; ¶ IL + Arg-treated
group; II Arg + IL-treated group. Significance (p < 0.05)
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with hematoxyline and eosin (H&E) for examination of
any histopathological changes.
Statistical analysis
Data were expressed as mean ± standard error of the mean
(SEM) by the multiple comparisons one-way analysis of
variance (ANOVA) with probability (p) values < 0.05
considered statistically significant. (Pairwise compari-
son applied and significance level adjusted for multiple
comparisons).
Results
The intravenous administration of 20 % IL into rats pro-
duced a significant increase in the lipid peroxidation
which was manifested by the elevation of blood and hep-
atic TBARS levels (1370 ± 55 nmol/L and 358.5 ±
10.6 nmol/g, respectively) as shown in Fig. 1. This sig-
nificant elevation of TBARS may be attributed to a sig-
nificant increase in the hepatic activity of CYP2E1 in IL
group (1.02 ± 0.01 IU/mg) as shown in Fig. 2. In
addition, Fig. 3 illustrates that IL administration resulted
in a significant decrease in hepatic content of NO and
hepatic activity of eNOS (0.147 ± 0.002 μmol/g and
0.004 ± 0.0001 IU/mg, respectively). Also, GSH content
and activities of GPx and SOD decreased significantly
below the control values in the blood and liver (Table 1).
This oxidative stress associated with a mark elevation in
blood and hepatic TNF-α levels (Table 2). Moreover, ad-
ministration of IL resulted in a significant increase in ac-
tivities of ALT and AST, as well as a significant decrease
in blood albumin level and elevation in urea and creatin-
ine levels, demonstrating liver and kidney dysfunction
(Figs. 4 and 5).
On the other hand, administration of Arg either before
or after IL ameliorated significantly uncontrolled eleva-
tion of TBARS content in the blood (374 ± 16 or 376 ±
17 nmol/L) and liver (135.7 ± 3.5 or 129.2 ± 6.1 nmol/g)
as well as the hepatic activity of CYP2E1 activity (0.32 ±
0.01 or 0.3 ± 0.02 IU/mg) and these values were close to
the levels of control rat group (3.74 ± 0.15 nmol/mL,
132.1 ± 5.3 nmol/g and 0.38 ± 0.01 IU/mg, respectively).
These effects were associated with a significant increase
in the levels of GSH and activities of GPx and SOD in
the blood and liver, compared to IL-treated rats (Figs. 1,
2 and Table 1). Also, hepatic NO level (1.649 ± 0.047 or
1.957 ± 0.073 μmol/g) and activity of hepatic eNOS
(0.05 ± 0.002 or 0.056 ± 0.002 IU/mg) increased signifi-
cantly compared to IL-treated rats (Fig. 3). In addition
to both plasma and hepatic levels of TNF-α were ame-
liorated to be near to normal values (Table 2). Further-
more, pre- and post-treatment using Arg maintained the
Fig. 3 Hepatic level of NO (μmol/g) and hepatic activity of eNOS (U/mg)
in various animal groups. All values are expressed as the mean ±
SEM and compared with: † control group; ‡ IL-treated group; §
Arg-treated group; ¶ IL + Arg-treated group; II Arg + IL-treated
group. Significance (p < 0.05)
Table 1 Levels of blood GSH (mg/L) and hepatic GSH (mg/g) and activities of blood & hepatic GPx and SOD (U/mg) in various
animal groups
Group Control IL Arg IL + Arg Arg + IL
Parameter
Blood GSH 24.8 ± 0.7‡,§,¶,II 15.7 ± 0.8†,§,¶,II 41.6 ± 0.9†,‡,¶,II 34 ± 0.9†, ‡, § 33.4 ± 1.6†, ‡, §
Hepatic GSH 0.15 ± 0.001‡,§,¶ 0.08 ± 0.01†,§,¶,II 0.2 ± 0.01†,‡,¶,II 0.19 ± 0.01†,‡,§,II 0.16 ± 0.01‡,§, ¶
Blood GPx 1.2 ± 0.01‡,§,¶,II 0.77 ± 0.03†,§,¶,II 1.3 ± 0.02†,‡ 1.33 ± 0.02†,‡,II 1.27 ± 0.01†, ‡,¶
Hepatic GPx 3.6 ± 0.15‡,§,¶,II 2.9 ± 0.07†,§,¶,II 5.5 ± 0.19†,‡,II 5.44 ± 0.14†,‡,II 4.8 ± 0.14†, ‡, §,¶
Blood SOD 1.23 ± 0.04‡,§ 1.1 ± 0.0†,§,¶,II 1.34 ± 0.0†,‡ 1.33 ± 0.04‡ 1.25 ± 0.04‡
Hepatic SOD 2.9 ± 0.07§,¶,II 2.6 ± 0.16§,¶,II 3.63 ± 0.09†,‡ 3.62 ± 0.9†,‡ 3.45 ± 0.1†,‡
All values are expressed as the mean ± SEM and compared with: † control group; ‡ IL-treated group; § Arg-treated group; ¶ IL + Arg-treated group; II Arg + IL-
treated group. Significance (p < 0.05)
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blood parameters of liver and kidney functions near to
control values indicating the restoration of their normal
functions (Figs. 4 and 5).
The histopathological study supported the results
obtained from the biochemical tests. Figure 6a shows
the normal architecture of hepatocytes of control rats,
whereas IL-treated group demonstrates small fatty
vacuoles in their cytoplasm and proliferation of bile
ducts. Also, steatosis was detected with microvascular
changes, including heavy inflammatory cells infiltra-
tion and clearing of cytoplasm and nuclei (necroin-
flammation) which are the histological hall markers of
steatohepatitis (Fig. 6b, c, and d). In addition, histo-
pathological examination of Arg group shows normal
hepatocytes with dilating sinusoids (Fig. 6e) and IL +
Arg and Arg + IL groups showed normal hepatocytes,
no steatosis and no bile duct proliferation but mild
inflammation in the group received IL after Arg
(Fig. 6f and g).
Discussion
Our previous study confirmed that intravenous adminis-
tration of 20 % IL resulted in the elevation of hepatic lipid
contents [20] which may deposit as lipid droplets in hepa-
tocytes [29]. The hepatic steatosis has become the main
cause of liver tests abnormalities [30] and increases the
sensitivity of the liver to injury, necrosis and inflammation
[10]. Hepatic steatosis leads to mitochondrial dysfunction
that plays a key role in abnormal generation of free radi-
cals [31]. In addition to mitochondrial dysfunction, the cu-
mulative effect of extramitochondrial fatty acids oxidation
represents a further increase in oxidative stress and mito-
chondrial impairment. The microsomal oxidation of fatty
acids was catalyzed by CYP2E1 which enhanced its ex-
pression in IL-induced hyperlipidemia as it was proved in
Ng et al. (2015) study on pigs [32].
Free radicals that initiate lipid peroxidation, depletion
of antioxidants, destruction of membrane and oxidative
damage of proteins lead to increased TBARS and de-
creased GSH level, GPx activity, SOD activity and albu-
min level after IL administration [33, 34]. This hepatic
Table 2 Levels of blood and hepatic TNF-α (pg/mg) in various animal groups
Group Control IL Arg IL + Arg Arg + IL
Parameter
Plasma TNF-α 4.5 ± 0.08 ‡ 14.8 ± 0.09†,§,¶,II 4.12 ± 0.13‡ 4.43 ± 0.06‡ 4.47 ± 0.09‡
Hepatic TNF-α 13.1 ± 0.6‡ 111 ± 0.49†,§,¶,II 11.9 ± 0.5‡ 13.02 ± 0.49‡ 24.6 ± 0.6‡
All values are expressed as the mean ± SEM and compared with: † control group; ‡ IL-treated group; § Arg-treated group; ¶ IL + Arg-treated group; II Arg + IL-
treated group. Significance (p < 0.05)
Fig. 4 Activities (U/mL) of ALT and AST and blood level of albumin
(mg/dl) in various animal groups0. All values are expressed as the
mean ± SEM and compared with: † control group; ‡ IL-treated
group; § Arg-treated group; ¶ IL + Arg-treated group; II Arg + IL-
treated group. Significance (p < 0.05)
Fig. 5 Blood level (mg/L) of creatinine, urea and urea nitrogen in
various animal groups. All values are expressed as the mean ± SEM
and compared with: † control group; ‡ IL-treated group; § Arg-treated
group; ¶ IL + Arg-treated group; II Arg + IL-treated group. Significance
(p < 0.05)
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oxidative stress is tightly associated with TNF-α-
mediated hepatic inflammation. TNF-α level was ele-
vated significantly in nonalcoholic fatty liver disease and
NASH in both humans and animals [13, 35]. Moreover,
proinflammatory cytokines activate transcription of
CYP2E1 [36] and iNOS. Over expression of iNOS en-
hances uncontrolled production of NO that favors the for-
mation of ONOO- when it is accompanied by increasing
O2
.- production; thus this reaction results in reduction of
NO availability and eNOS inactivation [37, 38]. In the
same time, hyperlipidemia which is developed after IL ad-
ministration leads to eNOS deficiency and subsequently,
decreases NO production [39, 40]. The resulting liver in-
jury is associated with bile duct proliferation [41]. Also,
hyperlipidemia that induces oxidative stress could exert
their injurious activities in other extrahepatic tissues such
as kidney. Scheuer et al. (2000) reported that high-fat diet
induced hyperlipidemia led to a rise in glomerular
tubulointerestitial generation of ROS leading to significant
chronic tubulointerestitial damage was associated with
elevation of serum level of urea and creatinine, indicating
renal dysfunction [42].
On the other hand, this study provides evidence that
daily administration of Arg whether before or after IL
injection, leads to various beneficial effects. Arg injection
resulted in a significant decrease in level of TBARS and
CYP2El activity indicating that Arg reduced oxidative
stress. This is consistent with previous results which
proved that pre- and post-treatment with Arg lowered
oxidative stress in animal model of hepatotoxicity [43].
Also, we found that this effect of Arg was associated
with induction of GSH and activities of SOD, GPx and
eNOS as well as NO level.
The Arg efficacy may be attributed to its direct anti-
oxidant effect that is due to the alpha-amino group, a
chemical moiety different from that necessary for NO
Fig. 6 Photomicrograph of rat liver (H&E stain × 400). a rat control liver. (b, c and d) IL-treated rat liver showing b fatty vacuoles (white arrows),
c inflammatory cell infiltration of portal tract (black arrow) and proliferation of bile duct (white arrows), and d necrosis (white arrow) with heavy
inflammation (black arrow). e Arg-treated rat liver showing normal hepatocytes. f IL plus Arg treated rat liver showing normal hepatocytes with dilated
blood vessel (arrow). g Arg plus IL treated rat liver showing normal hepatocytes with mild inflammation (arrow)
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generation. By acting as an antioxidant, Arg may scav-
enge O2
.- and thereby prevent eNOS-mediated O2
.- pro-
duction in an uncoupled status. In addition to its
indirect antioxidant effect by generation of NO [44], it is
reported that NO prevents oxidative stress in tissues
firstly by interrupting chain reaction of lipid peroxida-
tion via forming non radical novel nitrogen-containing
lipid adducts [45] and inhibiting the catalytic activity of
CYP2E1 [46, 47]. Secondly, NO may trigger the expres-
sion of antioxidant enzymes and novel nitrosative stress re-
sistance genes [48]. Lastly, NO augments the antioxidant
potency of GSH [49] by forming S-nitrosoglutathione
which is approximately 100 fold more potent than that of
GSH [50]. GSH is not only a major antioxidant, but also
upregulates GPx activity which protects against oxidation
and nitration reactions [51].
Therefore, the ROS-scavenging property of Arg to-
gether with its ability to sustain spare endogenous anti-
oxidants and decrease activity of the hepatic lipogenic
enzyme may inhibit oxidative liver damage and decrease
inflammation status [6, 47, 52]. Recent studies were
reported that Arg inhibits uncontrolled synthesis of
TNF-α thus block its deleterious effects [53, 54]. The ex-
perimental study of Ozsoy et al. (2011) [55] demon-
strated that i.p. administration of 500 mg/kg Arg for
7 days significantly prevented the elevation of liver en-
zymes and decreased bile duct proliferation and
leukocyte infiltration with no necrosis. Studies of Engin
et al (2011) [56] and Nanji et al (2001) [47] proved that
i.p. pre- and post-treatment of Arg provided a significant
treatment and protection against the liver injury
(necroinflammatory lesions, hepatocellular degeneration
and fibrosis). Infusion of Arg in experimental animals in-
creased renal plasma flow and glomerular filtration rate.
So animals were treated with gentamicin or cisplatin-
induced nephropathy together with Arg showed a sig-
nificant amelioration in renal functions as indicated by
blood urea nitrogen and creatinine levels [57, 58]. More-
over, this dose of Arg (500 mg/kg) has been clinically ap-
plied for several other human diseases [59–61].
Conclusions
In this study, we have demonstrated that 2 weeks of pre-
and post-treatment with Arg protected and treated liver
against IL-induced NASH. This Arg effect is most likely
attributed to its direct and NO dependent antioxidant
property.
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